Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14248MR)

This product GTTS-WQ14248MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14248MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1641MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACE-910
GTTS-WQ11251MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI4736
GTTS-WQ9189MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMGN853
GTTS-WQ9846MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JTX-2011
GTTS-WQ6919MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ6054MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CNTO 136
GTTS-WQ361MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ15575MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA UNII-FFX71LCS5T
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW